For some people, the use of cannabis leads to disorders, including addictive disorders. The trail of CBD, a non-psychotropic component of cannabis, is being considered to free these people from their addiction. Researchers have been looking at the potent doses to administer to measure its effectiveness and side effects. They are publishing their results in The Lancet.
There are two stages to the study.
In the first, 48 volunteers – consumers who wanted to quit – received either a placebo or CBD in different dosages: 200 mg, 400 mg, and 800 mg. At only 200 mg, this proved to be ineffective.
Therefore, the 34 new volunteers for the second phase tested only 3 configurations: placebo, 400 mg, and 800 mg. The placebo has a vital interest in distinguishing the effects induced by the active molecule, in this case, CBD, from those caused by other factors – which may be psychological, hence the expression “placebo effect.
With a dosage of 400 or 800 mg, participants were able to abstain longer than those on placebo. And the researchers did not find any particular side effects, although the doses tested were higher than those available on the market (estimated at 25 mg).
The results of our trial open up a new therapeutic strategy for managing problematic cannabis use in the clinical setting, says Tom Freeman, co-author of the study.